Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
0.020 SGD
32.18 M SGD
83.79 M SGD
191.18 M
About TALKMED
Sector
Industry
CEO
Peng Tiam Ang
Website
Headquarters
Singapore
Founded
2013
ISIN
SG2G61000003
FIGI
BBG005SX77F6
TalkMed Group Ltd. is an investment holding company, which engages in the provision of tertiary healthcare services. It operates through the Oncology Services and Cellular & Gene Therapy Related Products & Services segments. The Oncology Services segment offers assistance to Parkway Cancer Centre. The company was founded on September 10, 2013 and is headquartered in Singapore.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of 5G3 is 0.445 SGD — it hasn't changed in the past 24 hours. Watch TALKMED stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on SGX exchange TALKMED stocks are traded under the ticker 5G3.
5G3 stock has risen by 1.14% compared to the previous week, the last month showed zero change in price, over the last year TALKMED has showed a 17.11% increase.
5G3 stock is 0.00% volatile and has beta coefficient of 0.41. Track TALKMED stock price on the chart and check out the list of the most volatile stocks — is TALKMED there?
Today TALKMED has the market capitalization of 591.47 M, it has increased by 0.11% over the last week.
Yes, you can track TALKMED financials in yearly and quarterly reports right on TradingView.
TALKMED is going to release the next earnings report on Feb 25, 2025. Keep track of upcoming events with our Earnings Calendar.
5G3 net income for the last half-year is 9.80 M SGD, while the previous report showed 17.90 M SGD of net income which accounts for −45.24% change. Track more TALKMED financial stats to get the full picture.
TALKMED dividend yield was 5.79% in 2023, and payout ratio reached 90.53%. The year before the numbers were 7.50% and 129.87% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Dec 30, 2024, the company has 268.00 employees. See our rating of the largest employees — is TALKMED on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. TALKMED EBITDA is 35.27 M SGD, and current EBITDA margin is 49.66%. See more stats in TALKMED financial statements.
Like other stocks, 5G3 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade TALKMED stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So TALKMED technincal analysis shows the neutral today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating TALKMED stock shows the buy signal. See more of TALKMED technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.